European Pharmaceutical Manufacturer spoke to Staffan Widengren, director of corporate projects at Recipharm on the difficulties CDMOs are facing leading up to the EU FMD deadline, as well as the best way to handle them.
With the deadline for the European Falsified Medicines Directive (EU FMD) just around the corner, many CDMOs will find themselves struggling to meet compliance in time. Many businesses will have difficulty securing the level of investment required, as well as finalising negotiations with partners before the deadline.
In general, the barriers faced by Recipharm will be the same across the pharma industry, the most difficult of which being financial.